Chronic inflammatory demyelinating polyneuropathy in children: modern criteria for establishing diagnosis and pathogenetic treatment

Chronic inflammatory demyelinating polyneuropathy (CIDP) in children  is a rare disease, the genesis of which is autoimmune disorders. In CIDP, autoimmune inflammatory processes are mediated by disorders of both the cellular and humoral links of the immune system. Manifestations of demyelination can be observed on any segment of the peripheral nerve from the spinal roots to its distal parts. Currently, there are typical CIDP and CIDP variants. The diagnosis of CIDP is based on the results of the analysis of the patient’s anamnesis, neurological examination and electromyography (EMG) data, which indicate typical signs of demyelinating peripheral nerve damage. Recognition of the clinical phenotype of CIDP variants is crucial, since the diagnostic process and differential diagnosis may differ when compared to typical CIDP. In accordance with the recommendations of the European Academy of Neurology and Peripheral Nerve Society in 2021, fulfillment or incomplete fulfillment with diagnostic clinical and EMG criteria allows making the diagnosis in two categories — “CIDP” and “possible CIDP”. Supportive criteria are used to verify the diagnosis of CIDP only in patients with a “possible” diagnosis. If two supportive criteria are met, then the diagnosis is changed, for example, to “Typical CIDP” or one of the CIDP variants. In pediatric practice, of the supportive criteria, an objective response to treatment with immunomodulatory agents with an objective assessment of clinical improvement and cerebrospinal fluid analysis to detect protein-cell dissociation are most often used. As an induction of pathogenetic treatment of the first line in CIDP children, it is preferable to use 10% intravenous immunoglobulins (IVIg) with an IgG content of more than 95%. The earliest possible use of first-line pathogenetic treatment makes it possible to achieve remission and stop the progression of the disease. The use of adequate supportive treatment using IVIg or subcutaneous immunoglobulins help to stabilize the child’s condition and prevent the formation of neurological deficits.

Contribution:
Kurenkov A.L. — concept and design of the study, writing the text, editing;
Bursagova B.I. — writing the text, editing;
Podkletnova B.I. — editing;
Abdullaeva L.M. — editing.
All co-authors are responsible for the  integrity of all parts of the manuscript and approval of its final version.

Acknowledgements. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: April 11, 2022
Accepted: May 12, 2022
Published: June 30, 2022

1. McMillan H.J., Kang P.B., Jones H.R., Darras B.T. Childhood chronic inflammatory demyelinating polyradiculoneuropathy: combined analysis of a large cohort and eleven published series. Neuromuscul. Disord. 2013; 23(2): 103–11. https://doi.org/10.1016/j.nmd.2012.09.008

2. Ryan M.M., Pollard J.D., Ouvrier R.A. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy in childhood. In: Dale R.C., Vincent A., eds. Inflammatory and Autoimmune Disorders of the Nervous System in Children. London: Mac Keith Press; 2010: 406–30.

3. Nevo Y. Childhood chronic inflammatory demyelinating polyneuropathy. Eur. J. Paediatr. Neurol. 1998; 2(4): 169–77. https://doi.org/10.1016/s1090-3798(98)80016-0

4. Harada Y., Herrmann D.N., Logigian E.L. Pediatric CIDP: clinical features and response to treatment. J. Clin. Neuromuscul. Dis. 2017; 19(2): 57–65. https://doi.org/10.1097/CND.0000000000000179

5. McLeod J.G., Pollard J.D., Macaskill P., Mohamed A., Spring P., Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann. Neurol. 1999; 46(6): 910–3.

6. Clinical recommendations No. 358. Other inflammatory polyneuro pathies (Chronic inflammatory demyelinating polyneuropathy). Children; 2021. Available at: https://cr.minzdrav.gov.ru/recomend/358_2 (in Russian)

7. Van den Bergh P.Y.K., van Doorn P.A., Hadden R.D.M., Avau B., Vankrunkelsven P., Allen J.A., et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J. Peripher. Nerv. Syst. 2021; 26(3): 242–68. https://doi.org/10.1111/jns.12455

8. Cabasson S., Tardieu M., Meunier A., Rouanet-Larriviere M.F., Boulay C., Pedespan J.M. Childhood CIDP: Study of 31 patients and comparison between slow and rapid-onset groups. Brain Dev. 2015; 37(10): 943–51. https://doi.org/10.1016/j.braindev.2015.04.001

9. Dionne A., Nicolle M.W., Hahn A.F. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelina­ting polyneuropathy. Muscle Nerve. 2010; 41(2): 202–7. https://doi.org/10.1002/mus.21480

10. Doneddu P.E., Cocito D., Manganelli F., Fazio R., Briani C., Filosto M., et al. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J. Neurol. Neurosurg. Psychiatry. 2019; 90(2): 125–32. https://doi.org/10.1136/jnnp-2018-318714

11. Larue S., Bombelli F., Viala K., Neil J., Maisonobe T., Bouche P., et al. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur. J. Neurol. 2011; 18(6): 899–905. https://doi.org/10.1111/j.1468-1331.2010.03312.x

12. Lucke I.M., Wieske L., van der Kooi A.J., van Schaik I.N., Eftimov F., Verhamme C. Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy. J. Peripher. Nerv. Syst. 2019; 24(2): 174–9. https://doi.org/10.1111/jns.12325

13. Mal’mberg S.A., Rudenko E.N. Lumbosacral motor polyneuropathy. Nervno-myshechnye bolezni. 2012; (4): 59–65. (in Russian)

14. Pegat A., Boisseau W., Maisonobe T., Debs R., Lenglet T., Psimaras D., et al. Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: clinical characteristics, electrophysiological study, and response to treatment. J. Peripher. Nerv. Syst. 2020; 25(2): 162–70. https://doi.org/10.1111/jns.12380

15. Kurenkov A.L., Bursagova B.I., Kuzenkova L.M., Pak L.A., Uvakina E.V. Chronic inflammatory demyelinating polyneuropathy in childhood: criteria for diagnosis and approaches to pathogenetic treatment. Farmateka. 2019; 26(10): 32–7. https://doi.org/10.18565/pharmateca.2019.10.21-26 (in Russian)

16. Łukawska M., Potulska-Chromik A., Lipowska M., Hoffman-Zacharska D., Olchowik B., Figlerowicz M., et al. Pediatric CIDP: diagnosis and management. A single-center experience. Front. Neurol. 2021; 12: 667378. https://doi.org/10.3389/fneur.2021.667378

17. Bunschoten C., Jacobs B.C., Van den Bergh P.Y.K., Cornblath D.R., van Doorn P.A. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019; 18(8): 784–94. https://doi.org/10.1016/S1474-4422(19)30144-9

18. Hughes R., Bensa S., Willison H., Van den Bergh P., Comi G., Illa I., et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 2001; 50(2): 195–201. https://doi.org/10.1002/ana.1088

19. Breiner A., Barnett C., Bril V. INCAT disability score: a critical analysis of its measurement properties. Muscle Nerve. 2014; 50(2): 164–9. https://doi.org/10.1002/mus.24207

20. Vanhoutte E.K., Faber C.G., van Nes S.I., Jacobs B.C., van Doorn P.A., van Koningsveld R., et al. Modifying the Medical Research Council grading system through Rasch analyses. Brain. 2012; 135(Pt. 5): 1639–49. https://doi.org/10.1093/brain/awr318

21. Breiner A., Bourque P.R., Allen J.A. Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis. Muscle Nerve. 2019; 60(2): 180–3. https://doi.org/10.1002/mus.26488

22. Allen J.A., Ney J., Lewis R.A. Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis. Muscle Nerve. 2018; 57(4): 542–9. https://doi.org/10.1002/mus.25997

23. Broers M.C., Bunschoten C., Drenthen J., Beck T.A.O., Brusse E., Lingsma H.F., et al. Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy. Eur. J. Neurol. 2021; 28(6): 2065–73. https://doi.org/10.1111/ene.14796

24. Kurenkov A.L., Kuzenkova L.M., Bursagova B.I., Pak L.A., Podkletnova T.V., Abdullaeva L.M. Modern approaches to the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy in children (literature review). Meditsinskiy opponent. 2021; (4): 38–45. (in Russian)

25. Oaklander A.L., Lunn M.P., Hughes R.A., van Schaik I.N., Frost C., Chalk C.H. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst. Rev. 2017; 1(1): CD010369. https://doi.org/10.1002/14651858.CD010369.pub2

26. Silwal A., Pitt M., Phadke R., Mankad K., Davison J.E., Rossor A., et al. Clinical spectrum, treatment and outcome of children with suspected diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. Neuromuscul. Disord. 2018; 28(9): 757–65. https://doi.org/10.1016/j.nmd.2018.06.001

27. Gadian J., Kirk E., Holliday K., Lim M., Absoud M. Systematic review of immunoglobulin use in paediatric neurological and neurodevelopmental disorders. Dev. Med. Child Neurol. 2017; 59(2): 136–44. https://doi.org/10.1111/dmcn.13349

28. Léger J.M., De Bleecker J.L., Sommer C., Robberecht W., Saarela M., Kamienowski J., et al. Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study). J. Peripher. Nerv. Syst. 2013; 18(2): 130–40. https://doi.org/10.1111/jns5.12017

29. Dalakas M.C. Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and do­sing and challenges on stopping chronic IVIg therapy. Neurotherapeutics. 2021; 18(4): 2397–418. https://doi.org/10.1007/s13311-021-01108-4

30. van Schaik I.N., Bril V., van Geloven N., Hartung H.P., Lewis R.A., Sobue G., et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018; 17(1): 35–46. https://doi.org/10.1016/S1474-4422(17)30378-2

31. Hughes R.A., Mehndiratta M.M., Rajabally Y.A. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 2017; 11(11): CD002062. https://doi.org/10.1002/14651858.cd002062.pub4

32. Bansal V.K., Meriggioli M.N. Immunotherapy in the treatment autoimmune neuromuscular disease. In: Katirji B., Kaminski H.J., Ruff R.L., eds. Neuromuscular Disorders in Clinical Practice. New York: Springer; 2014: 341–62.

33. Mehndiratta M.M., Hughes R.A., Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 2015; 2015(8): CD003906. https://doi.org/10.1002/14651858.CD003906.pub4

34. Press R., Hiew F.L., Rajabally Y.A. Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice. Acta Neurol. Scand. 2016; 133(4): 228–38. https://doi.org/10.1111/ane.12519